Response to treatment
| . | All (n = 81)* . | TP53 cohort (n = 48)* . | Elderly cohort (n = 33)* . |
|---|---|---|---|
| Response after 6 mo, N (%) | |||
| CR | 0 (0) | 0 (0) | 0 (0) |
| PR | 51 (63.0) | 27 (56.3) | 24 (72.7) |
| PR-L | 26 (32.1) | 19 (39.6) | 7 (21.2) |
| SD | 1 (1.2) | 0 (0) | 1 (3.0) |
| Progression | 3 (3.7)† | 2 (4.2) | 1 (3.0) |
| Best response, N (%) | |||
| CR | 23 (28.4) | 14 (29.2) | 9 (27.3) |
| PR | 54 (66.7) | 32 (66.7) | 22 (66.7) |
| PR-L | 2 (2.5) | 1 (2.1) | 1 (3.0) |
| SD | 0 (0) | 0 (0) | 0 (0) |
| Progression | 2 (2.5) | 1 (2.1) | 1 (3.0) |
| . | All (n = 81)* . | TP53 cohort (n = 48)* . | Elderly cohort (n = 33)* . |
|---|---|---|---|
| Response after 6 mo, N (%) | |||
| CR | 0 (0) | 0 (0) | 0 (0) |
| PR | 51 (63.0) | 27 (56.3) | 24 (72.7) |
| PR-L | 26 (32.1) | 19 (39.6) | 7 (21.2) |
| SD | 1 (1.2) | 0 (0) | 1 (3.0) |
| Progression | 3 (3.7)† | 2 (4.2) | 1 (3.0) |
| Best response, N (%) | |||
| CR | 23 (28.4) | 14 (29.2) | 9 (27.3) |
| PR | 54 (66.7) | 32 (66.7) | 22 (66.7) |
| PR-L | 2 (2.5) | 1 (2.1) | 1 (3.0) |
| SD | 0 (0) | 0 (0) | 0 (0) |
| Progression | 2 (2.5) | 1 (2.1) | 1 (3.0) |
CR, complete response; PR, partial response; PR-L, partial response with lymphocytosis; SD, stable disease.
Of 86 enrolled, 5 patients were not evaluable for response. Two patients did not meet inclusion criteria and were removed from study, 2 patients died within the first 2 months, and 1 patient could not be evaluated because of newly diagnosed lung cancer. Supplemental Table 2 summarizes patient disposition.
Two patients never responded; 1 patient achieved a partial response at 2 mo and progressed (compared with 2-mo nadir) at 6 mo.